Literature DB >> 31994402

Proto-Oncogene Serine/Threonine Kinase PIM3 Promotes Cell Migration via Modulating Rho GTPase Signaling.

Yamei Dang1, Na Jiang1,2, Hao Wang1,2, Xuechun Chen1, Yan Gao2, Xiangyang Zhang2, Guoxuan Qin3, Yongmei Li1, Ruibing Chen1,2.   

Abstract

The proto-oncogene serine/threonine-protein kinase PIM3 plays critical roles in cancer, and it has been extensively exploited as a drug target. Here, we investigated the quantitative changes in the cellular proteome and phosphoproteome in liver cancer cells overexpressing PIM3 to obtain a better understanding of the regulatory functions of PIM3 and the underlying molecular mechanisms. This work depicted the landscape of gene expression and protein phosphorylation potentially regulated by PIM3. A signaling network analysis showed that PIM3 may coordinate various cellular processes, for example, signal transduction, cell cycle, apoptosis, and so forth. Intriguingly, quantitative phosphoproteomics revealed that the PIM3 overexpression elevated the phosphorylation of multiple Rho GTPase modulators that target RhoA, a central modulator of cell movement. Further investigations confirmed that PIM3 activated RhoA to subsequently regulate cytoskeletal rearrangements and cell migration. Taken together, this study comprehensively mapped the proteome and phosphoproteome regulated by PIM3 and revealed its role in promoting liver cancer cell migration and invasion by modulating Rho GTPase signaling.

Entities:  

Keywords:  HCC; PIM3; Rho GTPase; RhoA; bioinformatics; cell migration; metastasis; phosphoproteomics; quantitative proteomics; signaling transduction

Mesh:

Substances:

Year:  2020        PMID: 31994402     DOI: 10.1021/acs.jproteome.9b00821

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  3 in total

Review 1.  The role of Pim kinase in immunomodulation.

Authors:  Zhaoyun Liu; Mei Han; Kai Ding; Rong Fu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.

Authors:  Patricia de la Cruz-Ojeda; Tobias Schmid; Loreto Boix; Manuela Moreno; Víctor Sapena; Juan M Praena-Fernández; Francisco J Castell; Juan Manuel Falcón-Pérez; María Reig; Bernhard Brüne; Miguel A Gómez-Bravo; Álvaro Giráldez; Jordi Bruix; María T Ferrer; Jordi Muntané
Journal:  Cells       Date:  2022-08-28       Impact factor: 7.666

Review 3.  Quantitative proteomics characterization of cancer biomarkers and treatment.

Authors:  Xiao-Li Yang; Yi Shi; Dan-Dan Zhang; Rui Xin; Jing Deng; Ting-Miao Wu; Hui-Min Wang; Pei-Yao Wang; Ji-Bin Liu; Wen Li; Yu-Shui Ma; Da Fu
Journal:  Mol Ther Oncolytics       Date:  2021-04-20       Impact factor: 7.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.